Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review

被引:31
|
作者
Brown, T. [1 ]
Pilkington, G. [1 ]
Boland, A. [1 ]
Oyee, J. [1 ]
Smith, C. Tudur [2 ]
Dundar, Y. [1 ]
Richards, E. [3 ]
Yang, R. [4 ]
Dickson, R. [1 ]
机构
[1] Univ Liverpool, Liverpool Reviews & Implementat Grp, Liverpool L69 3BX, Merseyside, England
[2] Univ Liverpool, Dept Biostat, Liverpool L69 3BX, Merseyside, England
[3] Clatterbridge Ctr Oncol, Wirral, Merseyside, England
[4] Peking Univ, Inst Populat Res, Beijing 100871, Peoples R China
关键词
QUALITY-OF-LIFE; RANDOMIZED PHASE-II; LEUKEMIA GROUP-B; STAGE-III; CONCOMITANT CHEMORADIOTHERAPY; SEQUENTIAL CHEMORADIOTHERAPY; WEEKLY PACLITAXEL; TRIAL; CHEMOTHERAPY; CISPLATIN;
D O I
10.3310/hta17060
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Lung cancer is the most common cancer in the world and the second most common cancer diagnosed in the UK after breast cancer. In 2008, there were 40,806 new cases of lung cancer diagnosed in the UK, with 32,546 in England and 2403 in Wales.(1) Lung cancer is rarely diagnosed in people <40 years of age, and 86% of cases occur in people >60 years.(1) Table 1 provides an overview of lung cancer statistics in the UK. The European age-standardised incidence rate of lung cancer in 2008 was 45.6 per 100,000 population in England and 52.2 per 100,000 population in Wales.(1) The UK incidence rate in men is similar to incidence rates in most of Western Europe and is lower than incidence rates in most of Eastern Europe. 1 The UK incidence rate in women is one of the highest rates in the European Union.(1) There is an increased incidence of lung cancer in individuals from the lowest socioeconomic strata.(2) In 2008, around 65,000 individuals were living with lung cancer in the UK; 1 the majority of these individuals were men.(1)
引用
收藏
页码:1 / +
页数:101
相关论文
共 50 条
  • [41] Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer
    Xu, Bei
    Liu, Peng
    Yin, Yongmei
    Liu, Ping
    Shu, Yongqian
    BIOMEDICINE & PHARMACOTHERAPY, 2013, 67 (08) : 763 - 769
  • [42] Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
    Martinez, Pablo
    Peters, Solange
    Stammers, Timothy
    Soria, Jean-Charles
    CLINICAL CANCER RESEARCH, 2019, 25 (09) : 2691 - 2698
  • [43] S-1 plus cisplatin as first-line treatment of patients with advanced non-small cell lung cancer in Taiwan
    Lai, Chun-Liang
    Wei, Yu-Fen
    Hsia, Te-Chun
    Chang, Gee-Chen
    Wu, Jiun-Ting
    Chen, Jung-Yueh
    Chen, Yuh-Min
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (02) : E68 - E73
  • [44] Treatment of Locally Advanced Non-Small Cell Lung Cancer
    Tam, Kit
    Daly, Megan
    Kelly, Karen
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (01) : 45 - +
  • [45] Pemetrexed in first-line treatment of non-small cell lung cancer
    Esteban, Emilio
    Casillas, Marta
    Cassinello, Alejo
    CANCER TREATMENT REVIEWS, 2009, 35 (04) : 364 - 373
  • [46] Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer
    Ban, Heejung
    Kim, Kyu-Sik
    Oh, In-Jae
    Yoon, Seong-Hoon
    Lee, Boram
    Yu, Jinyeong
    Kim, Sunmin
    Lee, Ho-Sung
    Shin, Hong-Joon
    Park, Cheol-Kyu
    Kwon, Yong-Soo
    Kim, Yu-Il
    Lim, Sung-Chul
    Kim, Young-Chul
    THORACIC CANCER, 2014, 5 (06) : 525 - 529
  • [47] A Phase II Study of First-Line Chemotherapy with Weekly Carboplatin Plus Gemcitabine in Advanced Non-Small Cell Lung Cancer
    Mori, Kiyoshi
    Kamiyama, Yukari
    Kasai, Hisashi
    Kodama, Tetsuro
    CHEMOTHERAPY, 2012, 58 (01) : 78 - 83
  • [48] A Phase II Study of Weekly Docetaxel-Cisplatin As First-Line Treatment for Advanced Non-small Cell Lung Cancer
    Binder, Daniel
    Hackenthal, Matthias
    Graseck, Lutz
    Schweisfurth, Hans
    Schaeper, Christoph
    Kruell, Matthias
    Temmesfeld-Wollbrueck, Bettina
    Suttorp, Norbert
    Suttorp, Thomas
    Beinert, Thomas
    Hellriegel, Klaus-Peter
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : 1144 - 1147
  • [49] Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer
    Hayashi, H.
    Okamoto, I.
    Morita, S.
    Taguri, M.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2012, 23 (06) : 1537 - 1541
  • [50] Docetaxel (Taxotere®) as first-line therapy of advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    ONKOLOGIE, 2003, 26 : 26 - 32